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The compromise of renal microvascular 
structure has received considerable atten-
tion as a central and possibly causative 
feature of the development of chronic 
fibrotic kidney diseases. The reduction 
in capillary number has been reported 
in a number of chronic diseases and has 
been suggested to promote fibrosis in a 
variety of different ways, including the 
exacerbation of hypoxia.1,2 However, in 
the case of chronic kidney disease, the 
reduction of renal microvessels repre-
sents a chicken-and-egg dilemma: does 
microvessel dropout contribute to renal 
fibrosis, or does developing renal fibro-
sis impinge on renal capillary stability? 
The answer to this is not known, but data 
derived from acute or subtle injury mod-
els (folate, ischemia, nephrotoxin, tran-
sient angiotensin II) demonstrate a loss 
of capillaries that typically precedes the 
development of prominent fibrosis.3–5
These observations suggest that pres-
ervation or reversal of microvascular loss 
in a reversible injury model represents 
a sound strategy for ameliorating the 
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development of renal interstitial fibrosis, 
as well as addressing the role of vascular 
dropout as an antecedent event in pro-
gressing disease. We and others have dem-
onstrated that a number of factors with 
potential to influence vascular growth are 
altered in the early course of renal injury 
(in our experience using ischemia/reper-
fusion) and have argued that replacement 
or enhancement of these factors should 
maintain blood vessel structure and influ-
ence long-term outcome.1,6,7
Angiopoietin-1 is a potent angiogenic 
factor that interacts with the Tie-2 recep-
tor on endothelial cells. Angiopoietin-1 
has little or no proliferative potential but 
is a potent inhibitor of endothelial apop-
tosis.8 Angiopoietin-1 has promigratory 
effects on endothelial cells, and this may 
relate to its important activity facilitat-
ing tube formation during angiogenesis. 
Angiopoietin-1 stimulation also tightens 
endothelial junctions to reduce vascular 
leakiness, and this activity may be related 
to its anti-inflammatory effects. In general, 
angiopoietin-1 is considered a prominent 
vascular stabilizing factor in the develop-
ment of new blood vessels. Although the 
effects of angiopoietin-1 are complicated by 
the sometimes antagonistic activity of the 
related protein angiopoietin-2, the activities 
suggest that angiopoietin-1 is ideally suited 
as a molecule with potential to preserve 
blood vessels therapeutically.8
The regenerating kidney after an acute 
insult provides an opportunity to intervene 
at a potentially critical window of time in 
which remodeling events may influence 
vascular integrity and affect long-term 
function. Angiopoietin-1 expression is 
increased in a model of acute kidney injury 
induced by folate administration9 and 
recently was also shown to be increased in 
a model of ischemic acute kidney injury.7 
It is reasonable to hypothesize that such 
alterations in expression may represent 
an attempt to preserve the renal vascula-
ture undergoing active injury. It could be 
suggested that further enhancement of 
angiopoietin-1 would enhance vascular 
preservation following acute injury. As it 
turns out, it also represents an invitation 
for unanticipated complications.
Long et al.10 (this issue) have sought to 
address the potential therapeutic role of 
angiopoietin-1 using adenoviral delivery 
of a modified human angiopoietin-1 in a 
mouse model of folate-induced acute kid-
ney injury. This model is typically associ-
ated with an early (2–3 days) proliferation 
of cortical capillary endothelial cells fol-
lowed by a gradual regression of these cap-
illaries at longer times during recovery.9 
It was hypothesized that angiopoietin-1 
delivery may prevent the regression of 
capillaries in this model. This indeed was 
the case. Interestingly, the investigators 
also observed the simultaneous enhance-
ment of interstitial fibrosis characterized 
by collagen deposition and increased 
inflammatory-cell deposition.10
Although the authors may have antici-
pated different results, the implications of 
these findings are profound and impactful 
among those who are interested in vascu-
lar repair processes and their potential to 
affect kidney function. The study should 
raise considerable awareness of the com-
plicated nature of renal repair character-
ized by a complex milieu of cell types and 
altered chemical signaling. It forces atten-
tion to the fact that although angiogenesis 
may be observed in cultures in response 
to a given trophic factor, in vivo these 
molecules are promiscuous and may be 
highly inflammatory depending on the 
specific setting. It reminds us that renal 
injury has a prominent inflammatory 
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component that cannot be overlooked in 
the evaluation of potential interventions.
Importantly, angiopoietin-1 did, appar-
ently, preserve vascular integrity as would 
be predicted, but the added inflammatory 
activity is contradictory to its generally 
observed anti-inflammatory activity. The 
reason for this may represent an interesting 
area of future investigation. However, there 
is evidence that angiopoietin-1 may activate 
a cascade of inflammatory cytokines.11
In addition, the results should high-
light that therapy geared toward vascular 
preservation or repair may not be ubiqui-
tously applied across pathophysiological 
conditions. Clearly, as the authors noted,10 
there has already been considerable atten-
tion paid to the potential utility of vascu-
lar endothelial growth factor-A, which is 
protective to blood vessels and prevents 
further fibrosis in several, but not all, 
models investigated.12–14 In the case of 
angiopoietins, a novel and potent form, 
termed COMP-angiopoietin-1, has been 
shown to be effective in limiting fibrosis 
in a model of ureteral obstruction.15 How-
ever, as Long et al. point out,10 factors such 
as the establishment of an effective dose 
and the form of angiopoietin-1 adminis-
tered may also play an important role in 
outcome. The point of emphasis is that not 
all conditions are alike, and several other 
factors may influence vascular stability in 
disease models. One molecule is not likely 
to represent a panacea promoting vascular 
preservation without complications.
Several other questions are brought 
to mind in consideration of this area of 
investigation. The first question is whether 
therapy that targets the vasculature rep-
resents a useful approach at all, and if so, 
what is the basis for deciding what path-
ways should be targeted. Although vessel 
density is clearly compromised and asso-
ciated with hypoxia,1 vascular rarefaction 
does not occur as the sole and isolated event 
after injury with the potential to complicate 
chronic kidney function. Recent studies 
from our laboratory demonstrated that the 
manifestation of salt-sensitive hypertension 
and profound secondary chronic kidney 
disease was essentially nullified by admin-
istration of mycophenolate mofetil after the 
establishment of vascular injury induced by 
ischemia/reperfusion in rats.16 We interpret 
these results to suggest that both hypoxia 
occurring secondary to vascular loss and a 
complexity of infiltrating cells are required 
for the development of fulminant disease 
and that any of these may represent useful 
therapeutic targets.
If, as we believe, targeting the vasculature 
is important, the choice of molecules to be 
tested may require more specific informa-
tion regarding the nature of vascular drop-
out. For example, a more global perspective 
on the alterations of vasculotrophic fac-
tors in specific models is required, and 
therapies should use combinations of 
factors to compensate for alterations in 
the angiogenic milieu of the injured kid-
ney. Secondly, and related to the previous 
point, additional knowledge of the likely 
mechanism by which endothelial cells are 
lost would be helpful. Curiously, very little 
is known of the cellular events that lead 
to the loss of capillary endothelial cells 
in the setting of acute injury. Although 
an obvious hypothesis is that endothelial 
cells undergo apoptosis, aside from a sepsis 
model there is little direct evidence to sup-
port this contention.
As a final point of consideration, we 
would like to bring attention to the meth-
odology used by Long et al.10 to establish 
preserved vessel density in response to 
angiopoietin-1 treatment. These investi-
gators used CD31 immunohistochemistry 
to beautiful ly demonstrate that 
angiopoietin-1- exposed animals have a 
preserved or enhanced vasculature. This 
technique is well established, and we have 
used this approach in our own work. Nev-
ertheless, in light of the interesting, unex-
pected, and paradoxical results, perhaps 
further analysis is warranted. Because ves-
sels exist to support the perfusion needs 
of the organ, the physiological efficacy of 
these preserved vessels should be evaluated 
more thoroughly. In addition, given that 
there exist several populations of CD31-
positive circulating cells, including many 
that also express markers of monocyte 
or macrophage lineage, it is possible that 
the deposition of such cells, which may be 
termed ‘angiogenic macrophages,’17 could 
result in an enhanced inflammatory state 
masquerading as an angiogenic response.
Regardless, this interesting study high-
lights the promise and limitations of 
targeting the vasculature. In so doing, it 
defines important obstacles and allows us 
to generate new and testable paradigms to 
mitigate this perplexing problem.
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